Low invitation rates, not just low interest, sit at the center of women’s trial underrepresentation
A national survey of U.S. women points to a familiar but still undercorrected problem in clinical research: women may be willing to participate, yet they are rarely invited. In this cross-sectional online survey of 5,301 women aged 18 to 70 years, most respondents expressed at least some openness to joining a study, but actual access to research opportunities was strikingly limited. Only 11% said they had ever been invited to participate in a clinical trial, and just 7% reported that they had enrolled.
Those numbers matter because they separate attitude from opportunity. A research enterprise that depends on self-selection alone will continue to miss large portions of the population, especially when structural barriers shape who is even asked.
Willingness was common, but it was not evenly distributed
Among the 4,987 respondents who reported race, 77% identified as White, 14% as Black, 7% as Asian, and 2% as Other. Across the full sample, 23% said they would “definitely” participate in a clinical trial, while 60% answered “maybe.” On the surface, that suggests broad receptivity to research participation. The more consequential finding is that this willingness was not distributed uniformly across groups.
In adjusted analyses, Black women had lower willingness to participate than White women, with a β of −0.4 and a _P_ value of 0.0003. Higher educational attainment and multimorbidity were associated with greater willingness. The pattern hints at two different forces working at once: lived experience with the healthcare system may increase perceived relevance of research for women managing more than one condition, while educational exposure may improve understanding of what trial participation entails. For Black women, the lower willingness likely reflects more than individual preference; it is consistent with the accumulated weight of exclusion, mistrust, and unequal access to care and research settings.
Invitation remains the first bottleneck in the recruitment chain
A trial cannot recruit people who are never approached. This study makes that problem explicit. Despite relatively high self-reported openness, invitation rates were low enough to suggest that the current recruitment pipeline is failing long before consent is discussed. The gap between willingness and enrollment also indicates that many women who might accept participation never reach the point where study information is available in a usable, trustworthy form.
Structural barriers often begin with geography, clinic availability, time burden, transportation, caregiving responsibilities, and the simple fact that many ordinary care encounters do not include a conversation about research. Those barriers are not abstract. They determine whether a trial looks like a realistic option or a distant institutional exercise. In that setting, willingness becomes a necessary but insufficient condition for representation.
Race shaped preferred supports, motivators, and perceived barriers
Responses also differed by race in the kinds of resources women wanted, what motivated them, and what they perceived as obstacles. The abstract does not list every category, but the implication is clear: a single recruitment script will not serve all communities equally well. Women do not approach research participation with identical histories, expectations, or concerns, and recruitment materials that ignore those differences are likely to miss the audience they aim to reach.
Tailored engagement strategies may need to address trust directly, reduce logistical burden, and offer information in forms that feel relevant and respectful. For some women, the deciding factor may be practical assistance. For others, it may be whether the study seems aligned with their health priorities or whether the setting feels culturally safe. A one-size-fits-all approach leaves those distinctions unaddressed.
Sex-specific relevance may be one lever for improving engagement
Most respondents, 88%, endorsed women’s inclusion and sex-specific reporting in clinical research. That is a notable signal. It suggests that many women recognize the importance of evidence that reflects female biology, female symptom patterns, and female treatment responses. Clinical research has often treated sex as a variable to be adjusted for after the fact rather than a reason to design studies more thoughtfully from the start.
Making the relevance of women’s participation more explicit may help. If a potential participant understands that enrollment contributes to data that are more applicable to women’s health, the value proposition becomes easier to see. In practical terms, the promise of sex-specific reporting can function as both an informational tool and a trust-building strategy. It does not erase historical inequities, but it may help close the distance between abstract support for research and actual participation.
The burden of inequity shows up before consent is ever signed
This survey does not measure trial outcomes, adverse events, or retention. Its strength lies elsewhere: it maps the earliest barriers in the recruitment pathway. Those barriers include limited invitation, unequal willingness, and differential perceptions of research participation. When the front end of recruitment is skewed, later efforts to improve enrollment will continue to underperform.
The findings also raise a larger operational issue for investigators, sponsors, and health systems. If women are underrepresented because they are not being approached in ways that are understandable, credible, and practical, then recruitment failure is partly an implementation failure. Fixing it will require more than broader advertising. It will require trust-building, burden reduction, and recruitment models that account for race, education, health status, and the realities of daily life.
The study leaves unanswered which specific engagement strategies would most effectively shift willingness into enrollment, and whether the same barriers appear with equal force across different trial types. What it does establish is harder to ignore: women’s participation is constrained not only by choice, but by access, invitation, and the design of the research process itself.